US EditionMerus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On? - Merus (NASDAQ:MRUS)
- Merus reported interim phase 2 trial results on May 22, 2025, showing petosemtamab with pembrolizumab improves outcomes in head and neck cancer patients.
- The trial included 43 patients with PD-L1 positive advanced or returning head and neck squamous cell cancer and investigated a combination treatment approach aimed at improving current therapeutic outcomes.
- The treatment achieved a 63% overall response rate including six complete and 21 partial responses, with a 79% 12-month survival rate and median progression-free survival of nine months.
- Merus shares rose 34.9% to $56.11 amid favorable market reactions, while price targets increased to $88 and $110, and no significant overlapping toxicities were reported.
- These promising results suggest petosemtamab could become a new standard of care pending phase 3 trial data expected in 2026, with durable responses and manageable safety observed so far.
11 Articles
11 Articles
Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On? - Merus (NASDAQ:MRUS)
Merus N.V. (NASDAQ:MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for head and neck cancer. What To Know: The data, which will be formally presented at the 2025 ASCO Annual Meeting, showed a 63% overall response rate and a 79% 12-month overall survival rate among 43 evaluable patients with PD-L1+ ...Full story ava…
Inside Ottawa Valley
Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
· BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).…
#Innovations in Immunotherapy SYNC-T and Merus Lead the Charge Against Advanced Cancers,
'Immunotherapy Advances: SYNC-T for Prostate Cancer and Merus for Head and Neck Cancer' In recent developments in cancer therapeutics, innovative immunotherapy treatments have shown promising efficacy, highlighting a transformative era in managing metastatic cancers. Notably, Syncromune Inc. announced at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 that their SYNC-T therapy has demonstrated an impressive overall response …
Coverage Details
Bias Distribution
- 63% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
